Stock Update (NYSE:MRK): In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing

[Business Wire] – Merck said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial . . . → Read More: Stock Update (NYSE:MRK): In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing Similar Articles: Company Update (NYSE:MRK): Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28 Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Company Update: Merck & Co Inc (NYSE:MRK) – Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.